Picture of offices in the City of London

Open Access research that is better understanding work in the global economy...

Strathprints makes available scholarly Open Access content by researchers in the Department of Work, Employment & Organisation based within Strathclyde Business School.

Better understanding the nature of work and labour within the globalised political economy is a focus of the 'Work, Labour & Globalisation Research Group'. This involves researching the effects of new forms of labour, its transnational character and the gendered aspects of contemporary migration. A Scottish perspective is provided by the Scottish Centre for Employment Research (SCER). But the research specialisms of the Department of Work, Employment & Organisation go beyond this to also include front-line service work, leadership, the implications of new technologies at work, regulation of employment relations and workplace innovation.

Explore the Open Access research of the Department of Work, Employment & Organisation. Or explore all of Strathclyde's Open Access research...

Identification of the benzodiazepines as a new class of antileishmanial agent

Clark, Rachael L. and Carter, Katharine C. and Mullen, Alexander B. and Coxon, Geoffrey D. and Owusu-Dapaah, George and McFarlane, Emma and Dao Duong Thi, M. and Grant, M.H. and Tettey, J.N.A. and Mackay, Simon P. (2007) Identification of the benzodiazepines as a new class of antileishmanial agent. Bioorganic and Medicinal Chemistry Letters, 17 (3). pp. 624-627. ISSN 0960-894X

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

The continual increase in drug resistance; the lack of new chemotherapeutic agents; the toxicity of existing agents and the increasing morbidity with HIV co-infection mean the search for new antileishmanial agents has never been more urgent. We have identified the benzodiazepines as a structural class for antileishmanial hit optimisation, and demonstrated that their in vitro activity is comparable with the clinically used drug, sodium stibogluconate, and that the compounds are not toxic to macrophages.